Literature DB >> 18043259

Integrative oncogenomic approaches for accelerated cancer-gene discovery.

Lars Zender1, Scott W Lowe.   

Abstract

PURPOSE OF REVIEW: The completion of the human genome project has enabled several new technologies for studying cancer genetics and cancer genomes. However, genomic instability and heterogeneity of human tumors impedes a straightforward cataloging of cancer genes and possible therapeutic targets. Strategies enabling the distinction of causal genetic alterations from bystander genomic noise are needed and should significantly speed up the process of cancer-gene discovery. RECENT
FINDINGS: A series of recent papers described the development of integrative oncogenomic approaches based on innovative cancer mouse models and how these can be used to speed up the discovery of new cancer genes. In the presented studies, spontaneously acquired genetic alterations in mouse tumors of defined genetic origin are used to filter/prioritize relevant lesions from complex human cancer genomes. As will be discussed in this review, a great advantage of this approach is that pinpointed candidate genes can be functionally validated in the right genetic context in vivo, which significantly increases confidence for later therapeutic development efforts.
SUMMARY: The discussed approaches hold great promise to speed up the process of cancer-gene discovery and should be considered to complement time-consuming and costly endeavors like the Cancer Genome Project.

Entities:  

Mesh:

Year:  2008        PMID: 18043259      PMCID: PMC3285239          DOI: 10.1097/CCO.0b013e3282f31d5d

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  24 in total

1.  An open letter to cancer researchers.

Authors:  Stephen J Elledge; Gregory J Hannon
Journal:  Science       Date:  2005-10-21       Impact factor: 47.728

2.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.

Authors:  Michael T Hemann; Anka Bric; Julie Teruya-Feldstein; Andreas Herbst; Jonas A Nilsson; Carlos Cordon-Cardo; John L Cleveland; William P Tansey; Scott W Lowe
Journal:  Nature       Date:  2005-08-11       Impact factor: 49.962

3.  Essential role for oncogenic Ras in tumour maintenance.

Authors:  L Chin; A Tam; J Pomerantz; M Wong; J Holash; N Bardeesy; Q Shen; R O'Hagan; J Pantginis; H Zhou; J W Horner; C Cordon-Cardo; G D Yancopoulos; R A DePinho
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

4.  Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice.

Authors:  N G Deane; M A Parker; R Aramandla; L Diehl; W J Lee; M K Washington; L B Nanney; Y Shyr; R D Beauchamp
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

Review 5.  N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation.

Authors:  L Verna; J Whysner; G M Williams
Journal:  Pharmacol Ther       Date:  1996       Impact factor: 12.310

6.  Oncogene-induced liver neoplasia in transgenic mice.

Authors:  E P Sandgren; C J Quaife; C A Pinkert; R D Palmiter; R L Brinster
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

7.  Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation.

Authors:  Robert Lucito; John Healy; Joan Alexander; Andrew Reiner; Diane Esposito; Maoyen Chi; Linda Rodgers; Amy Brady; Jonathan Sebat; Jennifer Troge; Joseph A West; Seth Rostan; Ken C Q Nguyen; Scott Powers; Kenneth Q Ye; Adam Olshen; Ennapadam Venkatraman; Larry Norton; Michael Wigler
Journal:  Genome Res       Date:  2003-09-15       Impact factor: 9.043

8.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.

Authors:  Catherine M Shachaf; Andrew M Kopelman; Constadina Arvanitis; Asa Karlsson; Shelly Beer; Stefanie Mandl; Michael H Bachmann; Alexander D Borowsky; Boris Ruebner; Robert D Cardiff; Qiwei Yang; J Michael Bishop; Christopher H Contag; Dean W Felsher
Journal:  Nature       Date:  2004-10-10       Impact factor: 49.962

9.  Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.

Authors:  W S Pear; J P Miller; L Xu; J C Pui; B Soffer; R C Quackenbush; A M Pendergast; R Bronson; J C Aster; M L Scott; D Baltimore
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

10.  Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.

Authors:  R Wang; L D Ferrell; S Faouzi; J J Maher; J M Bishop
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

View more
  10 in total

1.  Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation.

Authors:  Hua Gao; Goutam Chakraborty; Ai Ping Lee-Lim; Konstantinos J Mavrakis; Hans-Guido Wendel; Filippo G Giancotti
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-05       Impact factor: 11.205

Review 2.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

3.  MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.

Authors:  Peter Olson; Jun Lu; Hao Zhang; Anny Shai; Matthew G Chun; Yucheng Wang; Steven K Libutti; Eric K Nakakura; Todd R Golub; Douglas Hanahan
Journal:  Genes Dev       Date:  2009-09-15       Impact factor: 11.361

Review 4.  Our changing view of the genomic landscape of cancer.

Authors:  Daphne W Bell
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

5.  Copy number variation has little impact on bead-array-based measures of DNA methylation.

Authors:  E Andrés Houseman; Brock C Christensen; Margaret R Karagas; Margaret R Wrensch; Heather H Nelson; Joseph L Wiemels; Shichun Zheng; John K Wiencke; Karl T Kelsey; Carmen J Marsit
Journal:  Bioinformatics       Date:  2009-06-19       Impact factor: 6.937

Review 6.  Using functional genetics to understand breast cancer biology.

Authors:  Alan Ashworth; Rene Bernards
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-02       Impact factor: 10.005

7.  AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.

Authors:  M Z Xu; S W Chan; A M Liu; K F Wong; S T Fan; J Chen; R T Poon; L Zender; S W Lowe; W Hong; J M Luk
Journal:  Oncogene       Date:  2010-11-15       Impact factor: 9.867

8.  Comparative oncogenomic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discovery.

Authors:  GuangJun Zhang; Sebastian Hoersch; Adam Amsterdam; Charles A Whittaker; Eline Beert; Julian M Catchen; Sarah Farrington; John H Postlethwait; Eric Legius; Nancy Hopkins; Jacqueline A Lees
Journal:  PLoS Genet       Date:  2013-08-29       Impact factor: 5.917

Review 9.  The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities.

Authors:  Michele De Palma; Douglas Hanahan
Journal:  Mol Oncol       Date:  2012-02-04       Impact factor: 6.603

10.  KANK1 inhibits cell growth by inducing apoptosis through regulating CXXC5 in human malignant peripheral nerve sheath tumors.

Authors:  Zhibin Cui; Yingjia Shen; Kenny H Chen; Suresh K Mittal; Jer-Yen Yang; GuangJun Zhang
Journal:  Sci Rep       Date:  2017-01-09       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.